Physician perceptions to use of trastuzumab in HER2+breast cancer in India

被引：0
|
作者：
Ramanjinappa, N. [1 ]
Agarwal, J. [1 ]
Upveja, K. H. [1 ]
机构：
[1] Viatris, Dept Med Affairs, Bengaluru, India
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
20P
引用
收藏
页码：S1437 / S1437
页数：1
相关论文
共 50 条
  • [21] A Review and Meta-analysis on Trastuzumab Resistance in Patients with HER2+Breast Cancer
    Holzbach, Alexandre
    Cima, Bernardo Perin
    Staffen, Mari Dalva
    Lindenau, Juliana Dal-Ri
    Muniz, Yara Costa Netto
    [J]. MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2023, 23 (11) : 1222 - 1236
  • [22] Involvement of microRNA-146a in trastuzumab resistance of HER2+breast cancer cells
    Cabello, P.
    Fores, J.
    Tormo, E.
    Pineda, B.
    Adam, A.
    Garrido, I.
    Pattanayak, B.
    Lluch, A.
    Eroles, P.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [23] Genomics of HER2+breast cancer
    Perou, C.
    [J]. CANCER RESEARCH, 2022, 82 (04)
  • [24] Heregulin-induced cell migration is prevented by trastuzumab and trastuzumab-emtansine in HER2+breast cancer
    Magali Mondaca, Joselina
    Castro Guijarro, Ana Carla
    Ines Flamini, Marina
    Matias Sanchez, Angel
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2021, 186 (02) : 363 - 377
  • [25] Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+breast cancer
    Lammers, Philip E.
    Dank, Magdolna
    Masetti, Riccardo
    Abbas, Richat
    Hilton, Fiona
    Coppola, Jennifer
    Jacobs, Ira
    [J]. BRITISH JOURNAL OF CANCER, 2018, 119 (03) : 266 - 273
  • [26] Subcutaneous versus intravenous administration of trastuzumab: preference of HER2+breast cancer patients and financial impact of its use
    Lazaro Cebas, Andrea
    Cortijo Cascajares, Susana
    Pablos Bravo, Siria
    Goyache Goni, Maria Del Puy
    Gonzalez Monterrubio, Gema
    Perez Cardenas, Maria Dolores
    Ferrari Piquero, Jose Miguel
    [J]. JOURNAL OF BUON, 2017, 22 (02): : 334 - 339
  • [27] Recent Insights into the Development of Preclinical Trastuzumab-Resistant HER2+Breast Cancer Models
    Gonzalez-Alonso, Paula
    Cristobal, Ion
    Zazo, Sandra
    Martin-Aparicio, Ester
    Chamizo, Cristina
    Madoz-Gurpide, Juan
    Rovira, Ana
    Eroles, Pilar
    Lluch, Ana
    Albanell, Joan
    Rojo, Federico
    [J]. CURRENT MEDICINAL CHEMISTRY, 2018, 25 (17) : 1976 - 1998
  • [28] Transcriptome and chromatin landscape changes associated with trastuzumab resistance in HER2+breast cancer cells
    Murad, Rabi
    Avanes, Arabo
    Ma, Xinyi
    Geng, Shuhui
    Mortazavi, Ali
    Momand, Jamil
    [J]. GENE, 2021, 799
  • [29] Risk of Heart Failure after Radiotherapy in Women with HER2+Breast Cancer Treated with Trastuzumab
    Aziz, K.
    Nowsheen, S.
    Herrmann, J.
    Ruddy, K. J.
    Mutter, R. W.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E39 - E40
  • [30] The basal phenotype as a clinically relevant indicator of trastuzumab resistance tu HER2+breast Cancer
    Choi, Michael Phillip
    Chung, Alice P.
    Bose, Shikha
    Han, Bingchen
    Qu, Ying
    Zhang, Xiao
    Cui, Xiaojiang
    Giuliano, Armando E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (26)
12345